Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first‐line systemic treatment or best supportive care: A multicenter international study
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Haematology"
DOI: 10.1111/ejh.13769
Abstract: This retrospective chart review examined real‐world healthcare resource utilization (HRU) in patients with AML ineligible for intensive therapy who received first‐line systemic therapy or best supportive care (BSC). read more here.
Keywords: best supportive; line systemic; ineligible intensive; first line ... See more keywords
Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle‐cell lymphoma ineligible for intensive therapy: A network meta‐analysis
Sign Up to like & getrecommendations! Published in 2023 at "European Journal of Haematology"
DOI: 10.1111/ejh.13953
Abstract: Because of lacking of head‐to‐head comparison among recently effective novel agents’ combination regimens for newly diagnosed patients with mantle‐cell lymphoma (MCL) who are ineligible for intensive therapy like autologous stem‐cell transplantation, the optimal option for… read more here.
Keywords: intensive therapy; ineligible intensive; newly diagnosed; diagnosed patients ... See more keywords
Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Therapeutic Advances in Hematology"
DOI: 10.1177/2040620719882822
Abstract: Acute myeloid leukemia (AML) is an aggressive hematological malignancy with a globally poor outcome, especially in patients ineligible for intensive chemotherapy. Until recently, therapeutic options for these patients included low-dose cytarabine (LDAC) or the hypomethylating… read more here.
Keywords: venetoclax; ineligible intensive; patients ineligible; intensive chemotherapy ... See more keywords
Transfusion Requirements and Hospitalization during First Line Treatment Among Newly Diagnosed Acute Myeloid Leukemia Patients Who Were Ineligible for Intensive Chemotherapy
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-117247
Abstract: Background: Newly diagnosed acute myeloid leukemia (ND AML) patients (pts) ineligible for intensive chemotherapy have limited treatment options. Most commonly used low intensity regimens are azacitidine (AZA), decitabine (DEC), or low-dose cytarabine (LDAC). These patients… read more here.
Keywords: ineligible intensive; treatment; median range; transfusion ... See more keywords
Phase 3 Trial of Gilteritinib Plus Azacitidine Vs Azacitidine for Newly Diagnosed FLT3mut+ AML Ineligible for Intensive Chemotherapy.
Sign Up to like & getrecommendations! Published in 2022 at "Blood"
DOI: 10.1182/blood.2021014586
Abstract: Treatment results for patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated (FLT3mut+) acute myeloid leukemia (AML) ineligible for intensive chemotherapy are disappointing. This multicenter, open-label, phase 3 trial randomized (2:1) untreated adults with FLT3mut+… read more here.
Keywords: aza; ineligible intensive; gil aza; flt3mut aml ... See more keywords
Costs per patient achieving remission with venetoclax-based combinations in newly diagnosed patients with acute myeloid leukemia ineligible for intensive induction chemotherapy.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2022.22021
Abstract: BACKGROUND: Venetoclax, in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC), received confirmatory approval in 2020 by the US Food and Drug Administration for the treatment of newly diagnosed acute myeloid leukemia (AML) in patients… read more here.
Keywords: per patient; ineligible intensive; costs per; newly diagnosed ... See more keywords
Predictors of the Overall Survival with Azacitidine Monotherapy in Untreated Acute Myeloid Leukemia Patients Ineligible for Intensive Therapy
Sign Up to like & getrecommendations! Published in 2022 at "Internal Medicine"
DOI: 10.2169/internalmedicine.0264-22
Abstract: Objective The prognostic factors for azacitidine in untreated acute myeloid leukemia (AML) patients ineligible for intensive therapy remain unknown. To identify prognostic factors for azacitidine monotherapy and assist clinicians in deciding whether to use azacitidine… read more here.
Keywords: intensive therapy; ineligible intensive; azacitidine monotherapy; patients ineligible ... See more keywords